JADBio

JADBio is a no-code machine learning platform that automates biomarker discovery and interprets their meaning based on specific research questions. It's geared in particular for speeding up drug discovery by processing multi-omics data, including genomics, transcriptome, metagenome, proteome, metabolome and phenotypic and clinical data.

JADBio includes features to help you find biomarkers efficiently:

• AutoML: Automates the entire machine learning process for those who don't know how.
• Multi-Omics Data Analysis: Processes different types of data to find insights as fast as possible.
• Feature Interpretation: Shows feature importance and visualizations to help you understand what's going on.
• Model Tuning: Offers single and multiple feature selection, light and heavy tuning options.

The platform is geared for researchers investigating a range of conditions, including cancer, immune and endocrine systems, metabolic and chronic diseases, infectious diseases and mental health. It can be used for tasks like early biomarker discovery, disease subtype identification, time-to-event analysis, disease monitoring and patient treatment response assessment.

JADBio pricing is tiered to accommodate different needs:

• Basic (Free): Full-featured, good for getting started, with data upload and wrangling, single feature selection and model visualization.
• Team ($2,199 per month): For teams of five or more, with extra features like multiple feature selection, heavy tuning, API access and custom analysis.
• Business Pro (Custom Pricing): For companies that need enterprise-level workflows, controls and integrations, with extra features like image and signal analysis and user-defined code.

JADBio also offers a Classroom Plan for educational use, with 30 floating licenses for collaboration between teachers and students.

With automated machine learning processes, JADBio is designed to make biomarker discovery easier and speed up drug development. That makes it a good option for researchers and life scientists.

Published on June 14, 2024